American Diabetes Association
DB20-1054R2_online_supplement_v29012021.pdf (1.16 MB)

Differences in Biomarkers of Inflammation Between Novel Subgroups of Recent-Onset Diabetes

Download (1.16 MB)
posted on 2021-02-19, 22:01 authored by Christian Herder, Haifa Maalmi, Klaus Strassburger, Oana-Patricia Zaharia, Jacqueline M. Ratter, Yanislava Karusheva, Mohamed A. Elhadad, Kálmán Bódis, Brenda W. C. Bongaerts, Wolfgang Rathmann, Sandra Trenkamp, Melanie Waldenberger, Volker Burkart, Julia Szendroedi, Michael Roden, GDS Group
A novel clustering approach identified five subgroups of diabetes with distinct progression trajectories of complications. We hypothesized that these subgroups differ in multiple biomarkers of inflammation. Serum levels of 74 biomarkers of inflammation were measured in 414 individuals with recent adult-onset diabetes from the German Diabetes Study (GDS) allocated to five subgroups based on data-driven analysis. Pairwise differences between subgroups for biomarkers were assessed with generalized linear mixed models before (model 1) and after adjustment (model 2) for the clustering variables. Participants were assigned to five subgroups: severe autoimmune diabetes (SAID, 21%), severe insulin-deficient diabetes (SIDD, 3%), severe insulin-resistant diabetes (SIRD, 9%), mild obesity-related diabetes (MOD, 32%) and mild age-related diabetes (MARD, 35%). In model 1, 23 biomarkers showed ≥1 pairwise difference between subgroups (Bonferroni-corrected p<0.0007). Biomarker levels were generally highest in SIRD and lowest in SIDD. All 23 biomarkers correlated with ≥1 of the clustering variables. In model 2, three biomarkers (CASP-8, EN-RAGE, IL-6) showed at least one pairwise difference between subgroups (e.g. lower CASP8, EN-RAGE and IL-6 in SIDD vs. all other subgroups, all p<0.0007). Thus, novel diabetes subgroups show multiple differences in biomarkers of inflammation, underlining a prominent role of inflammatory pathways in particular in SIRD.


The German Diabetes Study (GDS) was initiated and financed by the German Diabetes Center, (DDZ) which is funded by the German Federal Ministry of Health (Berlin, Germany), the Ministry of Culture and Science of the state North Rhine-Westphalia (Düsseldorf, Germany), and grants from the German Federal Ministry of Education and Research (Berlin, Germany) to the German Center for Diabetes Research e.V. (DZD).


Usage metrics



    Ref. manager